Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

  • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   43935   clinical trials with a EudraCT protocol, of which   7309   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools

    < Back to search results

    Print Download

    EudraCT Number:2011-000368-88
    Sponsor's Protocol Code Number:BEL114055
    National Competent Authority:Spain - AEMPS
    Clinical Trial Type:EEA CTA
    Trial Status:Ongoing
    Date on which this record was first entered in the EudraCT database:2012-05-21
    Trial results View results
    Expand All   Collapse All
    A. Protocol Information
    A.1Member State ConcernedSpain - AEMPS
    A.2EudraCT number2011-000368-88
    A.3Full title of the trial
    A Multi-center, Randomized Parallel Group, Placebo-Controlled Double-Blind Trial to Evaluate the Safety, Efficacy, and Pharmacokinetics of Belimumab, a Human Monoclonal Anti-BLyS Antibody, Plus Standard Therapy in Pediatric Patients with Systemic Lupus Erythematosus (SLE).
    Estudio multicéntrico, aleatorizado, de grupos paralelos, controlado con placebo, doble ciego para evaluar la seguridad, eficacia y farmacocinética de belimumab, un anticuerpo monoclonal humano anti-BLyS, más terapia estándar en pacientes pediátricos con lupus eritematoso sistémico (LES).
    A.3.1Title of the trial for lay people, in easily understood, i.e. non-technical, language
    A clinical research study to evaluate the effect of belimumab for the treatment of Systemic Lupus Erythematosus (SLE) in paediatric patients 5 to 17 years of age.
    Estudio para evaluar el efecto de belimumab para el tratatamiento del lupus eritematoso sistémico (LES) en pacientes pediátricos de 5 a 17 años.
    A.3.2Name or abbreviated title of the trial where available
    Belimumab in pediatric patients with SLE
    A.4.1Sponsor's protocol code numberBEL114055
    A.7Trial is part of a Paediatric Investigation Plan Yes
    A.8EMA Decision number of Paediatric Investigation PlanP/300/2011
    B. Sponsor Information
    B.Sponsor: 1
    B.1.1Name of SponsorGlaxoSmithKline, S.A.
    B.3.1 and B.3.2Status of the sponsorCommercial
    B.4 Source(s) of Monetary or Material Support for the clinical trial:
    B.4.1Name of organisation providing supportGlaxoSmithKline, Research and Development Ltd
    B.4.2CountryUnited Kingdom
    B.5 Contact point designated by the sponsor for further information on the trial
    B.5.1Name of organisationGlaxoSmithKline Research & Development Ltd
    B.5.2Functional name of contact pointClincial Trials Helpdesk
    B.5.3 Address:
    B.5.3.1Street AddressIron Bridge Road, Stockley Park West
    B.5.3.2Town/ cityUxbridge, Middlesex
    B.5.3.3Post codeUB11 - 1BU
    B.5.3.4CountryUnited Kingdom
    B.5.4Telephone number442089904466
    B.5.5Fax number442089904466
    D. IMP Identification
    D.IMP: 1
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation Yes
    D. name BENLYSTA? (belimumab)
    D. of the Marketing Authorisation holderGlaxo Group Limited
    D.2.1.2Country which granted the Marketing AuthorisationEuropean Union
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.1Product nameBenlysta (belimumab)
    D.3.2Product code GSK1550188
    D.3.4Pharmaceutical form Powder for solution for infusion
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPIntravenous use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNbelimumab
    D.3.9.1CAS number 356547-88-1
    D.3.9.2Current sponsor codeGSK1550188
    D.3.9.4EV Substance CodeSUB25607
    D.3.10 Strength
    D.3.10.1Concentration unit mg/ml milligram(s)/millilitre
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number80
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin No
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) Yes
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D. cell therapy medicinal product No
    D. therapy medical product No
    D. Engineered Product No
    D. ATIMP (i.e. one involving a medical device) No
    D. on Advanced therapies (CAT) has issued a classification for this product No
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product No
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.8 Information on Placebo
    D.8 Placebo: 1
    D.8.1Is a Placebo used in this Trial?Yes
    D.8.3Pharmaceutical form of the placeboSolution for infusion
    D.8.4Route of administration of the placeboIntravenous use
    E. General Information on the Trial
    E.1 Medical condition or disease under investigation
    E.1.1Medical condition(s) being investigated
    Systemic Lupus Erythematosus
    Lupus Eritematoso Sistémico
    E.1.1.1Medical condition in easily understood language
    E.1.1.2Therapeutic area Diseases [C] - Immune System Diseases [C20]
    MedDRA Classification
    E.1.2 Medical condition or disease under investigation
    E.1.2Version 14.1
    E.1.2Level PT
    E.1.2Classification code 10042945
    E.1.2Term Systemic lupus erythematosus
    E.1.2System Organ Class 10028395 - Musculoskeletal and connective tissue disorders
    E.1.3Condition being studied is a rare disease No
    E.2 Objective of the trial
    E.2.1Main objective of the trial
    - Evaluate the safety and tolerability of belimumab in the pediatric SLE population
    - Evaluate the pharmacokinetics of belimumab in the pediatric SLE population.
    - Evaluate the efficacy of belimumab in the pediatric SLE population
    - Evaluate the effects of belimumab on the quality of life in the pediatric SLE population.
    - Evaluación de la seguridad y la tolerabilidad de belimumab en la población pediátrica con LES.
    - Evaluación de la farmacocinética de belimumab en la población pediátrica con LES.
    - Evaluación de la eficacia de belimumab en la población pediátrica con LES.
    - Evaluación de los efectos de belimumab en la calidad de vida de la población pediátrica con LES.
    E.2.2Secondary objectives of the trial
    - To evaluate the sustained efficacy and safety of belimumab in the pediatric SLE population.
    - Evaluate the pharmacokinetics of belimumab in the pediatric SLE population.
    - Evaluate the effects of belimumab on the quality of life and fatigue in the pediatric SLE population.
    -Evaluación de la eficacia sostenida y la seguridad de belimumab en la población pediátrica con LES.
    - Evaluación de la farmacocinética de belimumab en la población pediátrica con LES.
    - Evaluación de los efectos de belimumab en la calidad de vida y la fatiga de la población pediátrica con LES.
    E.2.3Trial contains a sub-study No
    E.3Principal inclusion criteria
    Subjects eligible for enrolment in the study must meet all of the following criteria:
    1. Are 5 to 17 years of age
    2. Have or have had in series, 4 or more of the American College of Rheumatology (ACR) 11 criteria for the classification of SLE
    3. Have active SLE disease defined as a SELENA SLEDAI score >= 8 at screening.
    4. Have unequivocally positive autoantibody test results defined as an ANA titre >= 1:80 and/or a positive anti-dsDNA (>= 30 IU/mL) serum antibody test from 2 independent
    Time points as follows:
    - Positive test results from 2 independent time points within the study screening
    period. Screening results must be based on the study's central laboratory results.
    - One positive historical test result and 1 positive test result during the screening period.
    Historical documentation of a positive test of ANA (e.g., ANA by HEp-2 titre) or antidsDNA (e.g., anti-dsDNA by Farr assay) must include the date and type of the test, the name of the testing laboratory, numerical reference range, and a key that explains values provided as positive vs. negative OR negative, equivocal/borderline positive). Only unequivocally positive values as defined in the laboratory's reference range are acceptable; borderline values will not be accepted.
    5. Are on a stable SLE treatment regimen.
    "Stable treatment at baseline" consists of any of the following medications (alone or in combination) at a fixed dose for a period of at least 30 days prior to Day0:
    - Corticosteroids (prednisone or prednisone equivalent up to 0.5 mg/kg/day):
    - For subjects on SLE combination therapy, their stable steroid dose must be fixed within the range of 0 to 0.5mg/kg/day (prednisone or prednisone equivalent)
    - For subjects whose only SLE treatment is steroids, their stable steroid
    dose must be fixed within the range of 0.1-0.5mg/kg/day.
    - For those subjects on alternating day doses of steroids, use the average of 2 daily doses to calculate the average daily steroid dose.
    - ther immunosuppressive or immunomodulatory agents including methotrexate, azathioprine, leflunomide, mycophenolate (including mycophenolate mofetil, mycophenolate mofetil hydrochloride, and mycophenolate sodium), calcineurin inhibitors (e.g. tacrolimus, cyclosporine), sirolimus, oral cyclophosphamide, 6-mercaptopurine or thalidomide.
    - Anti-malarials (e.g. hydroxychloroquine, chloroquine, quinacrine)
    - Non-steroidal anti-inflammatory drugs (NSAIDs)
    - Pre-existing SLE medications must be stable for at least 30 days prior to Day 0.
    - Corticosteroids may be added as new medications or their doses adjusted only up to 30 days prior to Day 0.
    - New SLE therapy other than corticosteroids must not be added within 60 days of Day 0.
    (For the full section on Inclusion criteria, please refer to the Protocol on Page 28-31)
    Los sujetos elegibles para la inclusión en el estudio deberán satisfacer los siguientes criterios:
    1. Edad comprendida entre 5 y 17 años.
    2. Presentar o haber presentado de manera secuencial cuatro o más de los 11 criterios de clasificación del LES del Colegio Americano de Reumatología (ACR).
    3. Presentar LES activo, definido como una puntuación SELENA-SLEDAI >= 8 en la selección.
    4. Haber obtenido resultados positivos inequívocos en las pruebas de autoanticuerpos, definidos como un título de ANA >= 1:80 y/ o un resultado positivo en la prueba de anticuerpos séricos anti-ADNbc (>= 30 IU/ml) en dos puntos temporales del siguiente modo:
    - Resultados positivos en dos momentos temporales independientes dentro del periodo de selección del estudio. Los resultados de la selección se basarán en los resultados del laboratorio central del estudio.
    - Un resultado positivo en pruebas históricas y un resultado positivo en las pruebas realizadas en el transcurso del periodo de selección.
    La documentación histórica de un resultado positivo en la prueba de ANA (p. ej., ANA según título de HEp-2) o anticuerpos anti-ADNbc (p.ej., anti-ADNbc en la prueba de Farr) incluirá la fecha y el tipo de prueba, el nombre del laboratorio encargado de la misma, el intervalo numérico de referencia y una clave explicativa de los valores definidos como positivos frente a negativos O negativos, positivos equívocos/limítrofes). Únicamente se aceptarán los valores positivos inequívocos incluidos en el intervalo de referencia del laboratorio; se descartarán los valores limítrofes.
    5. Tratamiento estable para el LES.
    El ?tratamiento estable al inicio? se compondrá de cualquiera de estos fármacos (tanto solos como en combinación) a una dosis fija durante, al menos, 30 días antes del Día 0:
    5.1. Corticoesteroides (prednisona o equivalente de prednisona a una dosis máxima de 0,5 mg/kg/día):
    - En sujetos sometidos a terapia combinada para el LES, la dosis estable de corticoesteroides se encontrará dentro del intervalo de 0 a 0,5mg/kg/día (prednisona o equivalente de prednisona)
    - En los pacientes tratados únicamente con corticoesteroides, la dosis estable de corticoesteroides se situará dentro del intervalo de 0,1-0,5 mg/kg/día.
    - En los sujetos tratados con dosis de corticoesteroides en días alternos, se empleará el promedio de 2 dosis diarias para calcular la dosis media diaria de corticoesteroides.
    - Otros fármacos inmunosupresores o inmunomoduladores, como metotrexato, azatioprina, leflunomida, micofenolato (como micofenolato mofetilo, hidrocloruro de micofenolato mofetilo, y micofenolato sódico), inhibidores de calcineurina (p. ej. tacrolimus, ciclosporina), sirolimus, ciclofosfamida oral, 6-mercaptopurina o talidomida.
    -Antimaláricos (p. ej., hidroxicloroquina, cloroquina, quinacrina)
    -Antiinflamatorios no esteroideos (AINE)
    - Los fármacos previos para el LES deberán mantenerse estables durante, al menos, 30 días con anterioridad al Día 0.
    - Se permitirá la adición de corticoesteroides como nuevo tratamiento o la modificación de su dosis hasta 30 días antes del Día 0.
    - No se añadirán nuevos fármacos distintos de los corticoesteroides para el LES durante los 60 días anteriores al Día 0.
    (Para ver todos los Criterios de Inclusión, por favor consulte el Apartado 4.2 del protocolo).
    E.4Principal exclusion criteria
    Subjects meeting any of the following criteria must not be enrolled in the study:
    1. Have received treatment with any B-cell targeted therapy (e.g., rituximab, other anti-CD20 agents, anti-CD22 [epratuzumab], anti-CD5[alemtuzumab], BLyS-receptor fusion protein [BR3], TACI-Fc, or belimumab) at any time.
    2. Have received any of the following within 364 days of Day 0:
    - Abatacept.
    - A biologic investigational agent
    3. Have required 3 or more courses of systemic corticosteroids for concomitant conditions (e.g., asthma, atopic dermatitis) within 364 days of Day 0 (Topical or inhaled steroids are permitted).
    4. Have received intravenous (IV) cyclophosphamide within 90 days of Day 0.
    5. Have received any of the following within 90 days of Day 0:
    - Anti-TNF therapy (e.g., adalimumab, etanercept, infliximab).
    - Interleukin-1 receptor antagonist (anakinra).
    - Intravenous immunoglobulin (IVIG).
    -High dose prednisone (> 1.5 mg/kg/day) or equivalent.
    - Plasmapheresis.
    (For the full section on Exclusion criteria, please refer to the Protocol on Page 31-34)
    No podrán participar en el estudio aquellos sujetos que cumplan cualquiera de los siguientes criterios:
    1. Haber recibido tratamiento frente a los linfocitos B (p. ej., rituximab, otros fármacos anti-CD20, anti-CD22 [epratuzumab], anti-CD52 [alemtuzumab], proteína de fusión del receptor de BLyS [BR3], TACI Fc, o belimumab) en cualquier momento.
    2. Haber recibido tratamiento con cualquiera de los siguientes fármacos a lo largo de los 364 días anteriores al Día 0:
    - Abatacept.
    - Un agente biológico en fase de investigación.
    3. Haber requerido 3 o más ciclos de corticoesteroides sistémicos frente a trastornos concomitantes (p. ej., asma, dermatitis atópica) a lo largo de los 364 días anteriores al Día 0 (con excepción de corticoesteroides tópicos o inhalados que están permitidos).
    4. Haber recibido tratamiento con ciclofosfamida por vía intravenosa (i.v.) a lo largo de los 90 días anteriores al Día 0.
    5. Haber recibido tratamiento con cualquiera de los siguientes fármacos a lo largo de los 90 días anteriores al Día 0:
    - Fármacos anti-TNF (p. ej., adalimumab, etanercept, infliximab).
    - Antagonista del receptor de interleucina-1 (anakinra).
    - Inmunoglobulina intravenosa (IGIV).
    - Prednisona en dosis altas (> 1,5 mg/kg/día) o equivalente.
    - Plasmaféresis.
    (Para ver todos los Criterios de Exclusión, por favor consulte el Apartado 4.3 del protocolo).
    E.5 End points
    E.5.1Primary end point(s)
    The primary efficacy endpoint is response rate at Week 52.
    A response is defined as:
    >=4 point reduction from baseline in SELENA SLEDAI score,
    No worsening (increase of < 0.30 points from baseline) in Physician?s Global Assessment PGA),
    No new BILAG A organ domain score or 2 new BILAG B organ domain scores compared with baseline
    El criterio principal de valoración de la eficacia es la tasa de respuesta en la semana 52, definida como:
    - Reducción de >= 4 puntos respecto al valor inicial de la puntuación SELENA-SLEDAI,
    - Ausencia de empeoramiento (aumento < 0,30 puntos respecto al inicio) en la evaluación global del médico (PGA),
    - Ausencia de nueva puntuación de dominio orgánico A del índice BILAG o 2 nuevas puntuaciones de dominio orgánico B del índice BILAG en comparación con el inicio.
    E.5.1.1Timepoint(s) of evaluation of this end point
    52 weeks
    52 semanas.
    E.5.2Secondary end point(s)
    1. Proportion of subjects meeting PRINTO/ACR Juvenile SLE Response Evaluation criteria for improvement in juvenile SLE using two different PRINTO/ACR Juvenile SLE Response Evaluation definitions of improvement
    a. At least 50% improvement in any 2 of 5 endpoints below and no more than 1 of the remaining worsening by more than 30%
    b. At least 30% improvement in 3 of 5endpoints below and no more than of the remaining worsening more than 30%.
    I. Percent change in Parent?s Global Assessment (ParentGA) at Week 52.
    II. Percent change in Physician?s Global Assessment (PGA) at Week 52.
    III. Percent change in SELENA SLEDAI score at Week 52.
    IV. Change in PedsQL physical functioning domain at Week 52
    V. Percent change in 24 hour proteinuria at Week 52 (g/24hour equivalent by spot urine protein to creatinine ratio).
    2. Proportion of subjects with a sustained SRI response
    3. Proportion of subjects with a sustained ParentGA response
    4. Safety of belimumab
    5. PK comparison with Adult PK
    6. PedsQL Multidimensional Fatigue Scale
    1. Proporción de sujetos que satisfacen los Variables de la Respuesta en el LES juvenil de PRINTO/ACR para la mejora del LES juvenil mediante dos definiciones diferentes de mejora incluidas en dichos criterios.
    a. Una mejora de, al menos, el 50% en 2 de los 5 Variables siguientes y empeoramiento superior al 30% en no más de 1 de los restantes.
    b. Una mejora de, al menos, el 30% en 3 de los 5 Variables siguientes y empeoramiento superior al 30% en no más de 1 de los restantes.
    I. Cambio porcentual de la evaluación global de los padres (ParentGA) en la semana 52.
    II. Cambio porcentual de la evaluación global del médico (PGA) en la semana 52.
    III. Cambio porcentual de la puntuación SELENA-SLEDAI en la semana 52.
    IV. Cambio del dominio de funcionamiento físico del PedsQL en la semana 52.
    V. Cambio porcentual de la proteinuria de 24 horas en la semana 52 (g/24 horas, equivalente al cociente proteína:creatinina).
    2. Proporción de pacientes con una respuesta mantenida del IRL.
    3. Proporción de pacientes con una respuesta mantenida de la ParentGA.
    4. Seguridad de belimumab.
    5. Comparación de la FC con la FC en el adulto.
    6. Escala multidimensional de fatiga para evaluar la calidad de vida pediátrica ? PedsQL.
    E.5.2.1Timepoint(s) of evaluation of this end point
    52 weeks
    52 semanas
    E.6 and E.7 Scope of the trial
    E.6Scope of the trial
    E.6.1Diagnosis No
    E.6.2Prophylaxis No
    E.6.3Therapy Yes
    E.6.4Safety Yes
    E.6.5Efficacy Yes
    E.6.6Pharmacokinetic Yes
    E.6.7Pharmacodynamic No
    E.6.8Bioequivalence No
    E.6.9Dose response No
    E.6.10Pharmacogenetic Yes
    E.6.11Pharmacogenomic No
    E.6.12Pharmacoeconomic No
    E.6.13Others No
    E.7Trial type and phase
    E.7.1Human pharmacology (Phase I) No
    E.7.1.1First administration to humans No
    E.7.1.2Bioequivalence study No
    E.7.1.3Other No
    E. trial type description
    E.7.2Therapeutic exploratory (Phase II) Yes
    E.7.3Therapeutic confirmatory (Phase III) No
    E.7.4Therapeutic use (Phase IV) No
    E.8 Design of the trial
    E.8.1Controlled Yes
    E.8.1.1Randomised Yes
    E.8.1.2Open No
    E.8.1.3Single blind No
    E.8.1.4Double blind Yes
    E.8.1.5Parallel group No
    E.8.1.6Cross over No
    E.8.1.7Other Yes
    E. trial design description
    Open label long-term extension
    E.8.2 Comparator of controlled trial
    E.8.2.1Other medicinal product(s) No
    E.8.2.2Placebo Yes
    E.8.2.3Other No
    E.8.2.4Number of treatment arms in the trial2
    E.8.3 The trial involves single site in the Member State concerned No
    E.8.4 The trial involves multiple sites in the Member State concerned Yes
    E.8.4.1Number of sites anticipated in Member State concerned2
    E.8.5The trial involves multiple Member States Yes
    E.8.5.1Number of sites anticipated in the EEA12
    E.8.6 Trial involving sites outside the EEA
    E.8.6.1Trial being conducted both within and outside the EEA Yes
    E.8.6.2Trial being conducted completely outside of the EEA No
    E.8.6.3If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned
    Russian Federation
    United Kingdom
    United States
    E.8.7Trial has a data monitoring committee Yes
    E.8.8 Definition of the end of the trial and justification where it is not the last visit of the last subject undergoing the trial
    The long term follow up portion of the study (Part B and Part C) is planned for a total of up to 10 years. However, the study will conclude earlier if all subjects continuing belimumab treatment have received at least 5 years of treatment with belimumab and if there are 15 or fewer subjects continuing to receive belimumab in the study.
    La duración prevista de las partes de seguimiento a largo plazo del estudio (Parte B y Parte C) será de 10 años. No obstante, el estudio se interrumpirá de forma prematura cuando todos los pacientes del grupo de belimumab hayan recibido, al menos, 5 años de tratamiento con este fármaco y cuando el número de pacientes que continúen el tratamiento con belimumab en el estudio sea igual o menor de 15.
    E.8.9 Initial estimate of the duration of the trial
    E.8.9.1In the Member State concerned years14
    E.8.9.1In the Member State concerned months0
    E.8.9.1In the Member State concerned days0
    E.8.9.2In all countries concerned by the trial years14
    E.8.9.2In all countries concerned by the trial months0
    E.8.9.2In all countries concerned by the trial days0
    F. Population of Trial Subjects
    F.1 Age Range
    F.1.1Trial has subjects under 18 Yes
    F.1.1Number of subjects for this age range: 100
    F.1.1.1In Utero No
    F.1.1.2Preterm newborn infants (up to gestational age < 37 weeks) No
    F.1.1.3Newborns (0-27 days) No
    F.1.1.4Infants and toddlers (28 days-23 months) No
    F.1.1.5Children (2-11years) Yes
    F. of subjects for this age range: 20
    F.1.1.6Adolescents (12-17 years) Yes
    F. of subjects for this age range: 80
    F.1.2Adults (18-64 years) No
    F.1.3Elderly (>=65 years) No
    F.2 Gender
    F.2.1Female Yes
    F.2.2Male Yes
    F.3 Group of trial subjects
    F.3.1Healthy volunteers No
    F.3.2Patients Yes
    F.3.3Specific vulnerable populations Yes
    F.3.3.1Women of childbearing potential not using contraception No
    F.3.3.2Women of child-bearing potential using contraception Yes
    F.3.3.3Pregnant women No
    F.3.3.4Nursing women No
    F.3.3.5Emergency situation No
    F.3.3.6Subjects incapable of giving consent personally Yes
    F. of subjects incapable of giving consent
    Please refer to Protocol page 31
    F.3.3.7Others No
    F.4 Planned number of subjects to be included
    F.4.1In the member state6
    F.4.2 For a multinational trial
    F.4.2.1In the EEA 35
    F.4.2.2In the whole clinical trial 100
    F.5 Plans for treatment or care after the subject has ended the participation in the trial (if it is different from the expected normal treatment of that condition)
    As per protocol
    Véase el protocolo.
    G. Investigator Networks to be involved in the Trial
    N. Review by the Competent Authority or Ethics Committee in the country concerned
    N.Competent Authority Decision Authorised
    N.Date of Competent Authority Decision2012-07-27
    N.Ethics Committee Opinion of the trial applicationFavourable
    N.Ethics Committee Opinion: Reason(s) for unfavourable opinion
    N.Date of Ethics Committee Opinion2012-07-04
    P. End of Trial
    P.End of Trial StatusOngoing
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-2024 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands